As of September 30, 2026, LUMOSA THERAPEUTICS CO LTD carries a market capitalization of 13.77B, placing it among publicly traded companies globally. Its enterprise value stands at 13.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 13.77B |
| Enterprise Value | 13.17B |
LUMOSA THERAPEUTICS CO LTD's next confirmed earnings release is scheduled for March 1, 2027.
| Earnings Date | 3/1/2027 |
As of September 30, 2026, LUMOSA THERAPEUTICS CO LTD has 167.49M shares outstanding.
| Shares Outstanding | 167.49M |
These figures are as of September 30, 2026. The price-to-sales ratio is 425.88, and the price-to-book ratio stands at 11.61.
| PS Ratio | 425.88 |
| PB Ratio | 11.61 |
| P/TBV Ratio | 11.62 |
| P/FCF Ratio | -56.57 |
| P/OCF Ratio | -56.57 |
These figures are as of September 30, 2026. The EV/Sales ratio of 411.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.17B versus a market cap of 13.77B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 411.59 |
As of September 30, 2026, LUMOSA THERAPEUTICS CO LTD maintains a current ratio of 6.86, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.15, indicating conservative leverage, while an interest coverage ratio of -2,490.01 demonstrates limited ability to service its debt obligations.
| Current Ratio | 6.86 |
| Quick Ratio | 5.33 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -2,490.01 |
Over the twelve months ended September 30, 2026, LUMOSA THERAPEUTICS CO LTD posted a negative return on equity (ROE) of -28.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -25.99, reflecting losses generated across the asset base. The company generates approximately 820,717.95 in revenue per employee across its workforce of 39.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.14 indicates how many times LUMOSA THERAPEUTICS CO LTD sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -28.43 |
| Return on Assets (ROA) | -25.99 |
| Revenue Per Employee | 820,717.95 |
| Employee Count | 39.00 |
| Inventory Turnover | 0.14 |
As of the close on November 17, 2026, LUMOSA THERAPEUTICS CO LTD's stock has declined approximately 53.51% over the past 52 weeks. The 50-day moving average sits at 77.12, while the 200-day moving average is 114.04.
| 52-Week Price Change | -53.51% |
| 50-Day Moving Average | 77.12 |
| 200-Day Moving Average | 114.04 |
Over the twelve months ended September 30, 2026, LUMOSA THERAPEUTICS CO LTD generated 32.01M in revenue and converted that into -394.75M in net income, yielding earnings per share of -2.41. EBITDA reached -246.51M, while operating income came in at -257.13M.
| Revenue | 32.01M |
| Gross Profit | 18.34M |
| Operating Income | -257.13M |
| Pretax Income | -399.49M |
| Net Income | -394.75M |
| EBITDA | -246.51M |
| EBIT | -257.13M |
| Earnings Per Share (EPS) | -2.41 |
As of September 30, 2026, LUMOSA THERAPEUTICS CO LTD holds 601.23M in cash and equivalents against 1.74M in total debt, resulting in a net debt position of -113.85M. Total book value stands at 1.19B, with working capital of 660.14M providing operational flexibility.
| Cash & Cash Equivalents | 601.23M |
| Total Debt | 1.74M |
| Net Debt | -113.85M |
| Equity (Book Value) | 1.19B |
| Book Value Per Share | 7.08 |
| Working Capital | 660.14M |
LUMOSA THERAPEUTICS CO LTD produced -240.96M in operating cash flow over the twelve months ended September 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -240.96M - equivalent to -1.45 per share.
| Operating Cash Flow | -240.96M |
| Free Cash Flow | -240.96M |
| FCF Per Share | -1.45 |
Over the twelve months ended September 30, 2026, LUMOSA THERAPEUTICS CO LTD posted a gross margin of 57.30, reflecting its pricing power and cost economics. The operating margin of -803.33 and net profit margin of -1,233.29 provide insight into operational efficiency.
| Gross Margin | 57.30 |
| Operating Margin | -803.33 |
| Pretax Margin | -1,248.10 |
| Profit Margin | -1,233.29 |
| EBITDA Margin | -770.15 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -1.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to LUMOSA THERAPEUTICS CO LTD shareholders.
| Shareholder Yield | 0.05 |
| FCF Yield | -1.77 |
LUMOSA THERAPEUTICS CO LTD's most recent stock split took place on September 20, 2024 with a 500:501 split ratio.
| Last Split Date | 9/20/2024 |
| Split Ratio | 500:501 |
As of September 30, 2026, LUMOSA THERAPEUTICS CO LTD has an Altman Z-Score of 72.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 72.52 |
Already premium?